https://www.selleckchem.com/pr....oducts/Streptozotoci
The person responsible for identifying signs of morbidity was blinded to treatment assignments. Data were analyzed as a completely randomized design using MIXED (continuous) or GLIMIX (binomial) models of SAS 9.4. Average daily gain was similar between treatments (P = 0.91). No differences were found in dry matter intake (P = 0.14) nor in gain efficiency (P = 0.58). There were no differences (P = 0.74) in final body weights. Morbidity was similar at first, second, and third antimicrobial administration regardless of treatment (P